Is intravenous alteplase (tPA) indicated up to 9 hours after symptom onset in acute ischemic stroke when advanced imaging shows a small infarct core and a substantial penumbra, and what are the eligibility criteria?

Extended Stroke Window to 9 Hours for IV Alteplase

Based on the most recent high-quality evidence, IV alteplase can be administered up to 9 hours after stroke onset in carefully selected patients with salvageable brain tissue identified by perfusion imaging, though this represents an extension beyond current AHA/ASA guideline-approved time windows.

Current Guideline-Approved Time Windows

The 2018 AHA/ASA guidelines 1 establish Class I recommendations for IV alteplase only within:

• 0-3 hours: Standard dose 0.9 mg/kg (maximum 90 mg) for all eligible patients
• 3-4.5 hours: Same dosing for patients ≤80 years, without both diabetes and prior stroke, NIHSS ≤25, not on oral anticoagulants, and without imaging showing >1/3 MCA territory involvement

The guidelines explicitly state as a Class III contraindication that IV alteplase is NOT recommended when time last known well is >4.5 hours 1.

Emerging Evidence for Extended Window (4.5-9 Hours)

The HOPE Trial (2025) - Strongest Recent Evidence

The HOPE trial 2 provides the most recent and highest quality data supporting extended window thrombolysis:

• 372 patients treated 4.5-24 hours after onset with perfusion imaging selection
• Primary outcome: 40% achieved functional independence (mRS 0-1) with alteplase vs. 26% with standard care
• Adjusted risk ratio: 1.52 (95% CI 1.14-2.02, P=0.004)
• Absolute benefit: 14% more patients achieved excellent outcomes
• Safety trade-off: Symptomatic ICH increased to 3.8% vs. 0.51% (adjusted RR 7.34)
• Mortality: No difference (11% in both groups)

The EXTEND Trial (2019)

The EXTEND trial 3 was terminated early after enrolling 225 of 310 planned patients:

• Treatment window: 4.5-9 hours or wake-up stroke
• 35.4% achieved mRS 0-1 with alteplase vs. 29.5% with placebo (adjusted RR 1.44, P=0.04)
• Symptomatic ICH: 6.2% vs. 0.9% in placebo
• Used automated perfusion imaging for patient selection

Contradictory Evidence

The ECASS-4 trial 4 showed no significant benefit when using MRI-based selection 4.5-9 hours post-onset, though it was underpowered (stopped at 119 of 264 planned patients).

Eligibility Criteria for Extended Window (4.5-9 Hours)

If considering extended window thrombolysis based on emerging evidence, patients must meet ALL of the following:

Imaging Requirements

• Perfusion imaging demonstrating salvageable tissue (substantial penumbra with small infarct core)
• Automated perfusion software preferred for objective assessment
• No extensive early hypodensity on CT (avoid if >1/3 MCA territory involved)
• No intracranial hemorrhage

Clinical Criteria

• No initial plan for endovascular thrombectomy (EVT remains preferred for large vessel occlusion)
• Age ≥18 years
• Blood pressure controllable to <185/110 mmHg
• Glucose >50 mg/dL
• No absolute contraindications per standard criteria 1

Time Window Specifics

• Symptom onset 4.5-9 hours prior (or midpoint of sleep for wake-up stroke if within 9 hours)
• Treatment must be initiated as quickly as possible within this window

Critical Caveats and Pitfalls

Guideline vs. Research Evidence Gap

The 2018 AHA/ASA guidelines do not support treatment beyond 4.5 hours 1. The HOPE 2 and EXTEND 3 trials were published after these guidelines. The 2026 AHA/ASA guideline update 5 may incorporate this new evidence, but specific recommendations are not detailed in the provided excerpt.

Patient Selection is Paramount

• Without perfusion imaging showing salvageable tissue, extended window thrombolysis is NOT indicated
• The benefit depends entirely on identifying patients with tissue-at-risk
• Symptomatic ICH risk increases substantially (3.8-6.2% vs. <1% in standard care)

Large Vessel Occlusion

• If large vessel occlusion is present, endovascular thrombectomy is the priority treatment 6
• The extended window evidence applies primarily to patients NOT receiving thrombectomy

Asian vs. Non-Asian Populations

• HOPE trial 2 was conducted entirely in China
• Low-dose alteplase (0.6 mg/kg) commonly used in Asian populations showed comparable efficacy in patients <70 years 7, but standard 0.9 mg/kg dose is recommended per guidelines 1

Practical Algorithm for Extended Window Decision-Making

For patients presenting 4.5-9 hours after last known well:

1. Confirm no large vessel occlusion requiring EVT

   • If LVO present → proceed to thrombectomy evaluation

2. Obtain perfusion imaging (CT or MR perfusion)

   • Must demonstrate substantial penumbra with small core
   • Automated software analysis preferred

3. Verify standard eligibility criteria

   • BP <185/110 mmHg (or safely reducible)
   • No hemorrhage on imaging
   • No absolute contraindications

4. Assess risk-benefit in context of:

   • Accept 3-7x increased symptomatic ICH risk (absolute increase ~3-6%)
   • Potential 14% absolute increase in functional independence
   • No mortality difference

5. Informed consent discussion

   • Acknowledge this is beyond guideline-approved window
   • Explain increased bleeding risk
   • Document shared decision-making

6. Administer standard dose 0.9 mg/kg (maximum 90 mg)

   • 10% bolus over 1 minute
   • Remainder over 60 minutes

7. Post-thrombolysis monitoring per standard protocol 1

   • BP <180/105 mmHg for 24 hours
   • Neurological assessments
   • No antithrombotics for 24 hours

The strongest evidence supports extended window thrombolysis in perfusion-selected patients, but this remains outside current guideline recommendations and requires careful patient selection and informed consent.